Friday, 16 June 2017


Heptares Therapeutics is clinical stage company using innovative techniques in protein engineering and structure based drug design directed at G protein-coupled receptors (GPCRs). Heptares has built an exciting pipeline of new medicines across disease areas including Alzheimer's disease, migraine and cancer. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, Pfizer an…

Post a Comment